{"id":{"repo_id":"bu","oai_identifier":"oai:open.bu.edu:2144/49192"},"canonical_url":"https://search.ndltd.org/etd/bu/oai:open.bu.edu:2144/49192","repository":{"repo_id":"bu","name":"Boston University","base_url":"https://open.bu.edu/oai/request"},"display":{"title":"Costs and cost-effectiveness of interventions to improve HIV treatment adherence in Cape Town, South Africa","abstract":"BACKGROUND: Improving adherence to antiretroviral therapy (ART) is crucial for achieving HIV epidemic control in South Africa. The SUSTAIN trial aims to identify the most cost-effective package of evidence-based strategies for adherence monitoring (pharmacy refill monitoring (PRM), electronic adherence monitoring (EAM), viral load (VL) monitoring) and support (check-in texts (SMS), enhanced adherence counselling (EC)) for patients newly initiating ART. Participants were randomized to receive one of sixteen combinations of interventions using a multi-phase optimization strategy design. METHODS: First, a cost analysis of implementing SUSTAIN interventions for the first cohort (n=260) of participants was conducted from a health system perspective, using a micro-costing approach that employed three data collection methods: self-reported time and cost worksheets, independent staff observation, and discussions with staff during site visits. Second, a cost-effectiveness analysis was conducted using costing and adherence data from SUSTAIN participants to explore costs for achieving >80%, >90%, and >95% adherence for each intervention component. Third, a forward-looking costing model estimated costs for scaling up the interventions in a real-world setting (City of Cape Town) over a 10-year time horizon. All cost analyses were adjusted for inflation and discounted using an annual rate of 3%. RESULTS: The costs for one person-year of participation in SUSTAIN were $12 for PRM, $25 for VL monitoring, $162 for EAM, $16 for EC and $42 for SMS. Cost-effectiveness analyses showed PRM was cost-saving versus EAM and VL monitoring for achieving all categories of adherence. For support interventions, EC was cost-saving compared to SMS for achieving all categories of adherence. Estimated per annum future costs per patient ranged from $11–$25 for general program costs, $12–$20 for VL monitoring, $69–$122 for EAM, $3–$5 for PRM, $12–$14 for SMS, and $16–$31 for EC. A cost-effectiveness analysis of future costs found SMS would be more cost-saving than EC; the monitoring interventions remained the same. CONCLUSION: EAM was costliest due to high technology costs; however, these will decrease with mass production if scaled up. Pending final cost-effectiveness results from the main SUSTAIN trial, a differentiated approach based on cost and sensitivity of monitoring interventions could be considered for those restarting versus initiating ART. Support options require further investigation.","abstract_html":"BACKGROUND: Improving adherence to antiretroviral therapy (ART) is crucial for achieving HIV epidemic control in South Africa. The SUSTAIN trial aims to identify the most cost-effective package of evidence-based strategies for adherence monitoring (pharmacy refill monitoring (PRM), electronic adherence monitoring (EAM), viral load (VL) monitoring) and support (check-in texts (SMS), enhanced adherence counselling (EC)) for patients newly initiating ART. Participants were randomized to receive one of sixteen combinations of interventions using a multi-phase optimization strategy design. METHODS: First, a cost analysis of implementing SUSTAIN interventions for the first cohort (n=260) of participants was conducted from a health system perspective, using a micro-costing approach that employed three data collection methods: self-reported time and cost worksheets, independent staff observation, and discussions with staff during site visits. Second, a cost-effectiveness analysis was conducted using costing and adherence data from SUSTAIN participants to explore costs for achieving &gt;80%, &gt;90%, and &gt;95% adherence for each intervention component. Third, a forward-looking costing model estimated costs for scaling up the interventions in a real-world setting (City of Cape Town) over a 10-year time horizon. All cost analyses were adjusted for inflation and discounted using an annual rate of 3%. RESULTS: The costs for one person-year of participation in SUSTAIN were $12 for PRM, $25 for VL monitoring, $162 for EAM, $16 for EC and $42 for SMS. Cost-effectiveness analyses showed PRM was cost-saving versus EAM and VL monitoring for achieving all categories of adherence. For support interventions, EC was cost-saving compared to SMS for achieving all categories of adherence. Estimated per annum future costs per patient ranged from $11–$25 for general program costs, $12–$20 for VL monitoring, $69–$122 for EAM, $3–$5 for PRM, $12–$14 for SMS, and $16–$31 for EC. A cost-effectiveness analysis of future costs found SMS would be more cost-saving than EC; the monitoring interventions remained the same. CONCLUSION: EAM was costliest due to high technology costs; however, these will decrease with mass production if scaled up. Pending final cost-effectiveness results from the main SUSTAIN trial, a differentiated approach based on cost and sensitivity of monitoring interventions could be considered for those restarting versus initiating ART. Support options require further investigation.","abstract_has_math":true,"creators":["West, Rebecca Lynn"],"institution":"Boston University","degree_name":"Doctor of Public Health","degree_level":"doctoral","degree_discipline":"Public Health","degree_department":null,"school":null,"contributors":[],"advisors":["Sabin, Lora L."],"committee_chairs":[],"committee_members":[],"year":2024,"date_issued":"2024","date_published":"2024","updated_at":"2026-11-18T19:42:14Z","subjects":["Public health"],"languages":["en_US"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[{"key":"dc:identifier.orcid","label":"ORCID","values":["0000-0002-2958-0884"],"render_values":[{"text":"0000-0002-2958-0884","href":"https://orcid.org/0000-0002-2958-0884","code":true}]}]},"links":{"outbound_url":"https://hdl.handle.net/2144/49192","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/2144/49192","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://open.bu.edu/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aopen.bu.edu%3A2144%2F49192","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Sabin, Lora L."]},{"key":"dc:creator","label":"Author","values":["West, Rebecca Lynn"]},{"key":"dc:identifier.orcid","label":"ORCID","values":["0000-0002-2958-0884"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2024-08-28T19:19:59Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2024-08-28T19:19:59Z"]},{"key":"dc:date.issued","label":"Date","values":["2024"]},{"key":"dc:date.updated","label":"Dc Date Updated","values":["2024-08-28T16:13:36Z"]},{"key":"dc:type","label":"Dc Type","values":["Thesis/Dissertation"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Public Health"]},{"key":"thesis:degree_level","label":"Degree Level","values":["doctoral"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Public Health"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Boston University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Public health"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2144/49192"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["BACKGROUND: Improving adherence to antiretroviral therapy (ART) is crucial for achieving HIV epidemic control in South Africa. The SUSTAIN trial aims to identify the most cost-effective package of evidence-based strategies for adherence monitoring (pharmacy refill monitoring (PRM), electronic adherence monitoring (EAM), viral load (VL) monitoring) and support (check-in texts (SMS), enhanced adherence counselling (EC)) for patients newly initiating ART. Participants were randomized to receive one of sixteen combinations of interventions using a multi-phase optimization strategy design. METHODS: First, a cost analysis of implementing SUSTAIN interventions for the first cohort (n=260) of participants was conducted from a health system perspective, using a micro-costing approach that employed three data collection methods: self-reported time and cost worksheets, independent staff observation, and discussions with staff during site visits. Second, a cost-effectiveness analysis was conducted using costing and adherence data from SUSTAIN participants to explore costs for achieving >80%, >90%, and >95% adherence for each intervention component. Third, a forward-looking costing model estimated costs for scaling up the interventions in a real-world setting (City of Cape Town) over a 10-year time horizon. All cost analyses were adjusted for inflation and discounted using an annual rate of 3%. RESULTS: The costs for one person-year of participation in SUSTAIN were $12 for PRM, $25 for VL monitoring, $162 for EAM, $16 for EC and $42 for SMS. Cost-effectiveness analyses showed PRM was cost-saving versus EAM and VL monitoring for achieving all categories of adherence. For support interventions, EC was cost-saving compared to SMS for achieving all categories of adherence. Estimated per annum future costs per patient ranged from $11–$25 for general program costs, $12–$20 for VL monitoring, $69–$122 for EAM, $3–$5 for PRM, $12–$14 for SMS, and $16–$31 for EC. A cost-effectiveness analysis of future costs found SMS would be more cost-saving than EC; the monitoring interventions remained the same. CONCLUSION: EAM was costliest due to high technology costs; however, these will decrease with mass production if scaled up. Pending final cost-effectiveness results from the main SUSTAIN trial, a differentiated approach based on cost and sensitivity of monitoring interventions could be considered for those restarting versus initiating ART. Support options require further investigation."]},{"key":"dc:title","label":"Title","values":["Costs and cost-effectiveness of interventions to improve HIV treatment adherence in Cape Town, South Africa"]}]}],"canonical_facts":{"dc:contributor.advisor":["Sabin, Lora L."],"dc:creator":["West, Rebecca Lynn"],"dc:date.accessioned":["2024-08-28T19:19:59Z"],"dc:date.available":["2024-08-28T19:19:59Z"],"dc:date.issued":["2024"],"dc:date.updated":["2024-08-28T16:13:36Z"],"dc:description.abstract":["BACKGROUND: Improving adherence to antiretroviral therapy (ART) is crucial for achieving HIV epidemic control in South Africa. The SUSTAIN trial aims to identify the most cost-effective package of evidence-based strategies for adherence monitoring (pharmacy refill monitoring (PRM), electronic adherence monitoring (EAM), viral load (VL) monitoring) and support (check-in texts (SMS), enhanced adherence counselling (EC)) for patients newly initiating ART. Participants were randomized to receive one of sixteen combinations of interventions using a multi-phase optimization strategy design. METHODS: First, a cost analysis of implementing SUSTAIN interventions for the first cohort (n=260) of participants was conducted from a health system perspective, using a micro-costing approach that employed three data collection methods: self-reported time and cost worksheets, independent staff observation, and discussions with staff during site visits. Second, a cost-effectiveness analysis was conducted using costing and adherence data from SUSTAIN participants to explore costs for achieving >80%, >90%, and >95% adherence for each intervention component. Third, a forward-looking costing model estimated costs for scaling up the interventions in a real-world setting (City of Cape Town) over a 10-year time horizon. All cost analyses were adjusted for inflation and discounted using an annual rate of 3%. RESULTS: The costs for one person-year of participation in SUSTAIN were $12 for PRM, $25 for VL monitoring, $162 for EAM, $16 for EC and $42 for SMS. Cost-effectiveness analyses showed PRM was cost-saving versus EAM and VL monitoring for achieving all categories of adherence. For support interventions, EC was cost-saving compared to SMS for achieving all categories of adherence. Estimated per annum future costs per patient ranged from $11–$25 for general program costs, $12–$20 for VL monitoring, $69–$122 for EAM, $3–$5 for PRM, $12–$14 for SMS, and $16–$31 for EC. A cost-effectiveness analysis of future costs found SMS would be more cost-saving than EC; the monitoring interventions remained the same. CONCLUSION: EAM was costliest due to high technology costs; however, these will decrease with mass production if scaled up. Pending final cost-effectiveness results from the main SUSTAIN trial, a differentiated approach based on cost and sensitivity of monitoring interventions could be considered for those restarting versus initiating ART. Support options require further investigation."],"dc:identifier.orcid":["0000-0002-2958-0884"],"dc:identifier.uri":["https://hdl.handle.net/2144/49192"],"dc:language.iso":["en_US"],"dc:subject":["Public health"],"dc:title":["Costs and cost-effectiveness of interventions to improve HIV treatment adherence in Cape Town, South Africa"],"dc:type":["Thesis/Dissertation"],"thesis:degree_discipline":["Public Health"],"thesis:degree_level":["doctoral"],"thesis:degree_name":["Doctor of Public Health"],"thesis:institution_name":["Boston University"]},"updated_at":"2026-11-18T19:42:14Z"}